TY - JOUR
T1 - Use of landiolol hydrochloride, a new β-blocker, in coronary computed tomography angiography
AU - Isobe, Satoshi
AU - Sato, Kimihide
AU - Sugiura, Kaichiro
AU - Mimura, Takeo
AU - Kobayashi, Mikiko
AU - Meno, Chizuka
AU - Kato, Makoto
AU - Ishii, Hideki
AU - Murohara, Toyoaki
PY - 2010/3/4
Y1 - 2010/3/4
N2 - We investigated the usefulness of landiolol hydrochloride, an ultrashort-acting β1-selective agent, for coronary computed tomography angiography (CTA). Intravenous landiolol was administered to 133 patients before coronary CTA. Hemodynamic changes, adverse effects, image quality, and diagnostic accuracy for detection of coronary stenoses were evaluated. HR was significantly reduced during injection, but quickly recovered after cessation of landiolol. Neither significant changes in BP nor adverse effects were seen. The sensitivity, specificity, and positive and negative predictive values of coronary CTA for detection of significant stenoses were excellent, compared with invasive angiography. Therefore, our results show that intravenous landiolol administration gives a favorable image quality and facilitates diagnostic accuracy without causing adverse effects, indicating that landiolol is a useful premedication for coronary CTA.
AB - We investigated the usefulness of landiolol hydrochloride, an ultrashort-acting β1-selective agent, for coronary computed tomography angiography (CTA). Intravenous landiolol was administered to 133 patients before coronary CTA. Hemodynamic changes, adverse effects, image quality, and diagnostic accuracy for detection of coronary stenoses were evaluated. HR was significantly reduced during injection, but quickly recovered after cessation of landiolol. Neither significant changes in BP nor adverse effects were seen. The sensitivity, specificity, and positive and negative predictive values of coronary CTA for detection of significant stenoses were excellent, compared with invasive angiography. Therefore, our results show that intravenous landiolol administration gives a favorable image quality and facilitates diagnostic accuracy without causing adverse effects, indicating that landiolol is a useful premedication for coronary CTA.
UR - http://www.scopus.com/inward/record.url?scp=77249095251&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77249095251&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2008.06.088
DO - 10.1016/j.ijcard.2008.06.088
M3 - Article
C2 - 18703245
AN - SCOPUS:77249095251
SN - 0167-5273
VL - 139
SP - 196
EP - 198
JO - International Journal of Cardiology
JF - International Journal of Cardiology
IS - 2
ER -